Free Access
Issue
Med Sci (Paris)
Volume 32, Number 3, Mars 2016
Page(s) 241 - 244
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20163203005
Published online 23 March 2016
  1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 ; 126 : 663–676. [CrossRef] [PubMed] [Google Scholar]
  2. Lin C, Yu C, Ding S. Toward directed reprogramming through exogenous factors. Curr Opin Genet Dev 2013 ; 23 : 519–525. [CrossRef] [PubMed] [Google Scholar]
  3. Soufi A, Donahue G, Zaret KS. Facilitators and impediments of the pluripotency reprogramming factors’ initial engagement with the genome. Cell 2012 ; 151 : 994–1004. [CrossRef] [PubMed] [Google Scholar]
  4. Mehlen P, Rama N. Nétrine-1 et guidage axonal : signalisation et traduction asymétrique. Med Sci (Paris) 2007 ; 23 : 311–316. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Rais Y, Zviran A, Geula S, et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2013 ; 502 : 65–70. [CrossRef] [PubMed] [Google Scholar]
  6. Ozmadenci D, Feraud O, Markossian S, et al. Netrin-1 regulates somatic cell reprogramming and pluripotency maintenance. Nat Commun 2015 ; 6 : 7398. [CrossRef] [PubMed] [Google Scholar]
  7. Fitamant J, Guenebeaud C, Coissieux MM, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008 ; 105 : 4850–4855. [CrossRef] [Google Scholar]
  8. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004 ; 431 : 80–84. [CrossRef] [PubMed] [Google Scholar]
  9. Castets M, Broutier L, Molin Y, et al. DCC constrains tumour progression via its dependence receptor activity. Nature 2012 ; 482 : 534–537. [Google Scholar]
  10. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013 ; 339 : 1567–1570. [CrossRef] [PubMed] [Google Scholar]
  11. Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014 ; 156 : 663–677. [CrossRef] [PubMed] [Google Scholar]
  12. Lapasset L, Milhavet O, Lemaitre JM. La reprogrammation vers la pluripotence peut-elle effacer la mémoire d’une vie antérieure ? Med Sci (Paris) 2010 ; 26 : 902–903. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. David L. John De Vos J. La reprogrammation, un jeu de hasard ? Med Sci (Paris) 2013 ; 29 : 405–410. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Broutier L, Castets L. DCC : come back d’un gène suppresseur de tumeur controversé. Med Sci (Paris) 2012 ; 28 : 465–468. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.